Stereotaxis, Inc.
STXS
AMEX·Healthcare·Medical - Instruments & Supplies·Mkt cap $136.1M
$1.39
▲ 0.00%
P/E
-5.68
Mkt Cap
$136.1M
52-Wk Range
$1.24–$3.59
52-Week Range
$1.24 - $3.59
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 51.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary robotic magnetic navigation technology with established clinical validation and market adoption
- Integrated ecosystem combining robotic systems, imaging, catheters, and information management for comprehensive interventional lab solutions
- Strong intellectual property portfolio and strategic partnerships (Osypka AG) supporting product innovation and market expansion
- Established relationships with major hospitals and interventional centers globally through direct sales and distribution networks
- High switching costs and customer lock-in through integrated system architecture and specialized training requirements
Bear Case
1 risk
- Average volatility.
Growth
Moderate growth ahead
Strong revenue growth (20% YoY)
Value
Deep value opportunity - significant discount to sector peers
Momentum
Falling
-21.9% over 3m
Quality
Strong
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying STXS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 10, 2026
AUG 11, 2026
Reported EPS of -$0.05 vs -$0.05 consensus (0.0% surprise). Revenue of $7.7M vs $8.3M expected (-8.1%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
0.0%
Revenue trend · last 8Q
—
+39%
+9%
+95%
-19%
+36%
-16%
-13%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$9.2M
$6.3M
$7.5M
$8.8M
$7.5M
$8.6M
$6.3M
$7.7M
Margins · last 8Q
Gross
58.5%
Operating
-59.6%
Profit
-62.4%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Citi · Aug 27, 2026
vs Industry
How STXS stacks vs Medical - Instruments & Supplies
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.